Mixed UK reimbursement outlook for Pfizer's Mylotarg

The UK’s health technology assessor, The National Institute of Health and Care Excellence (NICE), has published draft guidance recommending Mylotarg (gemtuzumab ozogamicin) in combination with chemo as a treatment for certain acute myeloid leukaemia (AML) patients.

If finalized, the decision means that Pfizer’s (NYSE: PFE) targeted oncology agent would be reimbursed for routine use through the country’s national healthcare provider, the National Health Service.

The good news for Pfizer was tempered by the exclusion of patients whose disease has ‘intermediate cytogenetic status,’ approximately 65% of the eligible patient population.